Spencer Group Podcast
Matt McCarty & Jono Pagden Discuss Private Equity & Pharma
Over the past two decades, we’ve seen cycles of investment highs and lows, but is the recent slowdown in private equity funding for pharmaceutical technology and services one of the longest and most significant yet? In this episode, we dive into the macroeconomic and sector-specific pressures influencing this decline, from geopolitical interest rates and pharmaceutical pricing challenges to valuation gaps and a scarcity of quality assets.
With early signs of renewed confidence, we explore the key levers driving market recovery, the threats that could derail momentum, and the hottest trends shaping the future of pharma investment. Is this the turning point for private equity in life sciences? .
TESTIMONIALS
What Our Clients Say
“
"I wanted to make sure that whoever was going to take on this huge project was someone with the commitment we needed to achieve the scalability and someone that we could trust. I knew that the Spencer Group was that partner.
The fact that 20 years later we are still working with a trusted partner is testament to the fact that it works."
John Blakeley, Board Member, PharmaForceIQ
"They’re an outstanding recruitment partner with over 20 years’ experience and a deep understanding of the eClinical landscape, a deep understanding of me and the businesses in which I have worked. I trust them to deliver high calibre candidates with the right experience, skills and cultural values first time.
Our partnership has helped me consistently build stable, high performing global teams across the eClinical market."
Ian Jennings, SVP, Suvoda
+44 (0)118 935 9444